Barclays Sticks to Their Hold Rating for Blueprint Medicines (BPMC)

Barclays analyst Peter Lawson maintained a Hold rating on Blueprint Medicines (BPMC – Research Report) today and set a price target of $129.00. The company’s shares closed yesterday at $128.21.

Confident Investing Starts Here:

• Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
• Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter

According to TipRanks, Lawson is an analyst with an average return of -7.3% and a 38.91% success rate. Lawson covers the Healthcare sector, focusing on stocks such as Arcus Biosciences, Iovance Biotherapeutics, and Blueprint Medicines.

Currently, the analyst consensus on Blueprint Medicines is a Hold with an average price target of $129.67, representing a 1.14% upside. In a report released on June 5, Morgan Stanley also maintained a Hold rating on the stock with a $129.00 price target.

Based on Blueprint Medicines’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $149.41 million and a net profit of $496 thousand. In comparison, last year the company earned a revenue of $96.12 million and had a net profit of $89.14 million

Based on the recent corporate insider activity of 64 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BPMC in relation to earlier this year. Earlier this month, Percy H. Carter, the CSO of BPMC sold 2,659.00 shares for a total of $340,032.92.